BSE Live
Mar 27, 16:01Prev. Close
165.35
Open Price
163.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:56Prev. Close
165.20
Open Price
164.05
Bid Price (Qty.)
163.08 (14946)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Marksans Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 16.32 | 4.48 | |
| Diluted EPS (Rs.) | 16.32 | 4.48 | |
| Cash EPS (Rs.) | 22.33 | 9.03 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 52.15 | 15.43 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 52.15 | 15.43 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 191.51 | 73.33 | |
| PBDIT/Share (Rs.) | 34.75 | 16.20 | |
| PBIT/Share (Rs.) | 29.20 | 11.67 | |
| PBT/Share (Rs.) | 19.89 | 5.10 | |
| Net Profit/Share (Rs.) | 16.32 | 4.48 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 18.14 | 22.09 | |
| PBIT Margin (%) | 15.24 | 15.91 | |
| PBT Margin (%) | 10.38 | 6.95 | |
| Net Profit Margin (%) | 8.52 | 6.10 | |
| Return on Networth / Equity (%) | 31.30 | 29.02 | |
| Return on Capital Employed (%) | 12.67 | 9.10 | |
| Return on Assets (%) | 8.79 | 5.55 | |
| Total Debt/Equity (X) | 1.28 | 2.79 | |
| Asset Turnover Ratio (%) | 103.12 | 90.87 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 1.80 | 1.16 | |
| Quick Ratio (X) | 1.11 | 0.72 | |
| Inventory Turnover Ratio (X) | 4.93 | 5.25 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 100.00 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 485.54 | 82.39 | |
| EV/Net Operating Revenue (X) | 2.03 | 1.12 | |
| EV/EBITDA (X) | 11.18 | 5.09 | |
| MarketCap/Net Operating Revenue (X) | 1.66 | 0.57 | |
| Retention Ratios (%) | 100.00 | 100.00 | |
| Price/BV (X) | 6.11 | 2.72 | |
| Price/Net Operating Revenue | 1.66 | 0.57 | |
| Earnings Yield | 0.05 | 0.11 |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth